ABL Bio Inc.
KOE: 298380.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Sang Hoon Lee
- Employees
- 102
- Headquarters
- Seongnam, South Korea
- IPO year
- 2018
- Market cap
- ₩7.2T
- Website
- http://www.ablbio.com
Loading 298380…
Loading profile data…Frequently asked questions about 298380
What does ABL Bio Inc. (298380.KQ) do?
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.
Where does 298380.KQ trade?
ABL Bio Inc. (298380.KQ) trades on the KOSDAQ.
What sector is 298380.KQ in?
ABL Bio Inc. (298380.KQ) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of ABL Bio Inc.?
Sang Hoon Lee is the chief executive officer of ABL Bio Inc. (298380.KQ).
Where is ABL Bio Inc. headquartered?
ABL Bio Inc. is headquartered in South Korea.
Does 298380.KQ pay a dividend?
ABL Bio Inc. (298380.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 298380.KQ go public?
ABL Bio Inc. (298380.KQ) completed its initial public offering in 2018.